Products
-
Rimegepant*CAS:1289023-67-1
-
Ubrogepant*CAS:1374248-77-7
-
Elacestrant*CAS:722533-56-4
-
AT037
CPG 2216CAS:332437-00-0
-
AT035
CPG 2007CAS:455348-63-7
-
AT019
Vutrisiran*CAS:1867157-35-4
-
AT018
Patisiran*CAS:1420706-45-1
-
AT017
Givosiran*CAS:1639325-43-1
-
AT008
Inclisiran*CAS:1639324-58-5
-
AT003
CPG 1018CAS:937402-51-2
-
AT005
Nusinersen*CAS:1258984-36-9
Product Pipeline
-
R&D
-
Pilot
-
Validation
-
DMF file
-
Commercial
-
Peptides
-
Small Molecules
-
Oligonucleotides
-
Bivalirudin
-
Cetrorelix Acetate
-
Eptifibatide
-
Lanreotide Acetate
-
Octreotide Acetate
-
Thymalfasin
-
Atosiban Acetate
-
Desmopressin Acetate
-
Liraglutide*
-
Semaglutide*
-
Tirzepatide*
-
Edotreotide
-
Oxytocin
-
Retatrutide*
-
Teriparatide
-
Difelikefalin*
-
Pegcetacoplan*
-
Plecanatide
-
Setmelanotide*
-
Teduglutide
-
Ziconotide
-
Agomelatine
-
Atorvastatin Calcium
-
Epalrestat
-
Fulvestrant
-
Oseltamivir Phosphate
-
Sodium Picosulfate
-
Alogliptin Benzoate*
-
Roxadustat*
-
Sulindac
-
Ezetimibe
-
Risdiplam*
-
Baloxavir marboxil*
-
Elacestrant dihydrochloride*
-
Dydrogesterone
-
Elacestrant*
-
Orforglipron*
-
Rimegepant*
-
Ubrogepant*
-
Nusinersen*
-
CPG 1018
-
CPG 2007
-
CPG 2216
-
Givosiran*
-
Inclisiran*
-
Patisiran*
-
Vutrisiran*
*Disclaimer: Due to the limitation of patent protection, commercial production and sales will not be carried out for the time being, and will only be used for scientific research and administrative approval.
